Jumping ahead of AstraZeneca, AbbVie and J&J get a green light to market Imbruvica/Rituxan combo for rare lymphoma
Building on some solid data, AbbVie and J&J today landed an FDA OK to sell a chemo-free combination of their BTK inhibitor Imbruvica with Roche’s Rituxan for a rare and incurable type of non-Hodgkin’s lymphoma.
The agency came through after researchers posted an 82% survival rate after 30 months for patients with Waldenström’s macroglobulinemia — only 28% patients getting only Rituxan survived that long.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.